Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease

Climb Bio Inc (NASDAQ:CLYM) is one of the tiny stocks that are on fire right now. On April 7, Climb Bio received FDA Fast Track Designation for budoprutug, its investigational anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy/pMN. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill unmet medical needs. Currently, there are no FDA-approved therapies for pMN, a rare immune-mediated kidney disease affecting ~75,000 people in the US.

The FDA’s decision was supported by promising results from a Phase 1b study, where budoprutug achieved 100% peripheral B-cell depletion and clinical remission in all participating patients by week 48. The treatment also showed a favorable safety profile and durable reductions in proteinuria, suggesting its potential as a disease-modifying therapy. The Fast Track status will allow for more frequent interactions with the FDA and eligibility for priority review if supported by clinical data.

Budoprutug is currently being evaluated in PrisMN, a Phase 2 global open-label clinical trial. This study is assessing the drug’s efficacy in patients who have persistent proteinuria despite standard treatments, to identify the optimal dose for Phase 3 development. Climb Bio Inc (NASDAQ:CLYM) expects to release initial data from the PrisMN study in H2 2026.

Climb Bio Inc (NASDAQ:CLYM) is a clinical-stage biotechnology company. It is focused on developing therapies for immune-mediated diseases, with a pipeline centered on monoclonal antibodies targeting B-cell-driven conditions.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.